1. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
- Author
-
Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, and Louapre C
- Subjects
- Adult, Antibodies, Monoclonal, Humanized adverse effects, COVID-19 epidemiology, Female, France epidemiology, Humans, Immunologic Factors adverse effects, Interferons adverse effects, Italy epidemiology, Male, Meta-Analysis as Topic, Middle Aged, Multiple Sclerosis epidemiology, Multivariate Analysis, Protective Factors, Retrospective Studies, Risk Factors, Rituximab adverse effects, Severity of Illness Index, Antibodies, Monoclonal, Humanized pharmacology, COVID-19 physiopathology, Immunologic Factors pharmacology, Interferons pharmacology, Multiple Sclerosis drug therapy, Rituximab pharmacology
- Abstract
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon., (© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2021
- Full Text
- View/download PDF